Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2013: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
Outline of Final Research Achievements |
In order to renovate the clinical laboratory examination for malignant tumors, we clinically verified the originally developed biomarkers such as RB1CC1 and p62/SQSTM1, etc. In parallel, we also conducted the trial identification of unknown biomarkers for tumors using the model mice with genetic mutations caused by ENU. From a different side, gene expression in cancer and the stem cells (CSCs) was investigated by comparisons with normal cells through global transcriptomics and principal component analyses. We found that novel molecules are selectively expressed in cancer cells of different histotypes, and we made an application for Japanese patents about these molecular candidatesas promising therapeutic targets for cancer.
|